-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Generalized Anxiety Disorder (GAD) is a state of constant anxiety about trivial matters.
This anxiety has nothing to do with any specific surroundings, but is generally caused by excessive worry
.
There are four symptoms of generalized anxiety disorder: motor tension, nervous system overactivity, worry about the future, fear, and excessive alertness
child
Figure 1.
The prevalence of GAD
Biopharmaceutical company Mind Medicine recently revealed that the FDA has shelved a Phase IIb trial of lysergic acid diethylamine (LSD) for the treatment of generalized anxiety disorder (GAD)
.
The reason for this move is not yet clear, but the company said it expects to provide more details within 30 days
Biopharmaceutical company Mind Medicine recently revealed that the FDA has shelved a Phase IIb trial of lysergic acid diethylamine (LSD) for the treatment of generalized anxiety disorder (GAD)
The frustration of psychedelic adjuvant therapy
The frustration of psychedelic adjuvant therapyThis FDA move is the latest blow to the field of psychedelic adjuvant therapy
.
In November, due to safety issues with the experimental drug COMP360 of the pharmaceutical company COMPASS Pathways, the FDA held a negative attitude towards the drug
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5466469 https://firstwordpharma.
com/story/5466469 Leave a message here